{"id":"NCT02662556","sponsor":"Talphera, Inc","briefTitle":"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain","officialTitle":"A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03","primaryCompletion":"2016-06","completion":"2016-07","firstPosted":"2016-01-25","resultsPosted":"2017-03-15","lastUpdate":"2017-03-15"},"enrollment":140,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Moderate-to-severe Pain"],"interventions":[{"type":"DRUG","name":"sufentanil sublingual tablet 30 mcg","otherNames":["ST 30 mcg"]}],"arms":[{"label":"sufentanil sublingual tablet 30 mcg","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, open-label study in patients 40 years and older who are undergoing a surgical procedure.\n\nPatients may receive one dose of ST 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.","primaryOutcome":{"measure":"Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12).","timeFrame":"12-hours","effectByArm":[{"arm":"Sufentanil Sublingual Tablet (SST) 30 mcg","deltaMin":36.04,"sd":2.22}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":140},"commonTop":["Nausea","Dizziness","Headache","Pruritis","Oxygen saturation decreased"]}}